Tag Archives: Food and Drug Administration

Alzheimer’s Research: Where We’ve Failed and What’s To Come

health care, medicine

Alzheimer’s disease is a rapidly growing public health crisis. Today an estimated 5.4 million Americans live with the disease and, barring the development of medical breakthroughs to prevent, stop or slow Alzheimer’s disease by 2050, the number of people age 65 and older with Alzheimer’s disease may reach as high as 16 million people. What’s more, at a cost of $236 billion a year, Alzheimer’s is the most expensive disease in the nation with an Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

“Please Wait a Few Moments While Your Pill Prints”

Drugs

Since the late 1980’s, innovators have dreamed of living in a world where science could develop anything they want simply by pressing “print.” 3D printing has evolved to create an array of medical applications from prosthetics to printed bones and tissues, and now—3D printed pills. Three days ago, the Food and Drug Administration approved Spritam, the first 3D-printed drug expected to hit the market by early 2016. It was developed by Ohio based Aprecia Pharmaceuticals Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

FDA Acts on Biosimilars

Noonan-Headshot-high-res

The Biologics Price Competition and Innovation Act (BPCIA) deferred to the Food and Drug Administration with regard to implementing the particulars of how the biosimilar approval pathway would be implemented.  The U.S. Food and Drug Administration has issued a series of draft Guidances indicating how it was considering implementing the biosimilar approval pathway contained in the Act.  The Guidances were expressly “draft” in nature, and were the subject of public hearings with the Agency welcoming Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO Is Almost Here – What To Consider Before Entering New Therapeutic Areas

BIO International Convention

Over the past decade, the biopharmaceutical industry has witnessed a shift towards specialty care. From 2008 to 2014, FDA specialty drug approvals jumped from 33 percent to over 50 percent of all approvals. In 2014, the FDA approved a record 19 specialty care medicines. Given this new reality, companies are expanding the focus of their R&D into new therapeutic areas to address difficult-to-treat, specialty care conditions. Building successful franchises requires a strategic approach to determine the Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

New PhRMA report: Nearly 800 Cancer Medicines in Development

vaccines

A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) shows that biopharma companies are currently developing nearly 800 new medicines and vaccines for cancer. “In recent decades, we have seen great progress in developing effective cancer treatments that help extend lives, improve quality of life and increase productivity,” said PhRMA President and CEO John J. Castellani. “Continued research has expanded our knowledge of how cancer develops and how to target medicines for Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,